University of California San Francisco Give to UCSF

Join Dr. Jennie Taylor as she outlines what you need to know about Vorasidenib (VORANIGO®), the latest FDA-approved advancement that targets mutant IDH1 and IDH2 enzymes in the treatment of gliomas. Personal patient reflections will be weaved into the presentation and there will be time for Q&A.

Event Details


Zoom link will be emailed on the day before registration

UCSF promotes the exchange of diverse ideas and perspectives, acknowledging that the views and opinions of our guest speakers on campus are their own and may not reflect the perspective of the University. We embrace free speech in the pursuit of greater understanding, consistent with our obligations as a public university under the First Amendment.